CRUSH ReportsCRUSH Alerts 2.0CRUSH Industry ReportsCRUSHarmyContact Manager ApplicationMid-Market Manager ApplicationTarget Builder Application
 

Roche Group (RHHVF)

The Roche Group CRUSH Report is a Global 500 deep dive sales intelligence company profile and will help increase your sales leads and add more accounts in your sales pipeline while eliminating costly research time.

The Roche Group CRUSH Report contains insights to IT architectures, business and technology initiatives, corporate strategies, projects and budgets, org charts and key decision-maker contact info.

The Roche Group CRUSH Report allows IT sales and marketing professionals to:
  • Jump-start sales cycles in net new accounts
  • Expand footprints in existing customer accounts
  • Facilitate the strategic account planning process
  • Respond to RFPs & bids more effectively
  • Build better content into executive level presentations
  • Identify the presence of competitors & partners
The Roche Group CRUSH Report has the competitive intelligence needed for account planning within the Global 500. Target the right people, with the right message at the right time using our org charts, decision maker contact info, business drivers and IT landscapes.

Click here to download free sample CRUSH Reports

Roche Media News

Media Releases

Roche will report new data on important progress for people with advanced cancers at ASCO 2012
Wednesday May 16th 2012 01:15:00 AM

Roche today announced that the company will present important new data from studies of several of its cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1 to 5, 2012, in Chicago. At the meeting, data on Roche’s late-stage investigational and approved cancer medicines will be communicated in sessions that include 30 oral presentations.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Roche provides update on Phase III study of dalcetrapib
Monday May 7th 2012 01:00:00 AM

Roche today announced that following the results of the second interim analysis of the dalcetrapib dal-OUTCOMES Phase III trial, the independent Data and Safety Monitoring Board (DSMB) has recommended stopping the trial due to a lack of clinically meaningful efficacy. The dal-OUTCOMES trial evaluated the efficacy and safety profile of dalcetrapib when added to existing standard of care in patients with stable coronary heart disease (CHD) following an acute coronary syndrome (ACS). No safety signals relating to the dal-OUTCOMES trial were reported from the DSMB.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Roche reports positive study of RoACTEMRA given by subcutaneous injection
Thursday May 3rd 2012 01:00:00 AM

Roche today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) 162mg weekly compared to 8 mg/kg RoACTEMRA intravenous (IV) formulation every 4 weeks.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Roche decides not to extend its tender offer for Illumina, Inc.
Wednesday April 18th 2012 09:05:00 AM

Roche released the following statement based on preliminary estimates indicating the re-election of the incumbent directors of Illumina, Inc. (NASDAQ: ILMN) at the Illumina annual meeting

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Roche issues statement regarding Illumina offer
Thursday April 12th 2012 01:00:00 AM

Roche released the following statement regarding its pending offer for Illumina, Inc. (NASDAQ: ILMN)

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Roche on track for full-year targets - good sales growth in first quarter
Thursday April 12th 2012 01:00:00 AM

Group sales rise 2% at CER (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss francs. Excluding Tamiflu, sales growth is 3%.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Roche sends open letter to Illumina shareholders
Wednesday April 11th 2012 04:00:00 PM

Roche today sent an open letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to vote the GOLD proxy card for Roche’s independent director nominees and other proposals at the 2012 Illumina annual meeting to be held on 18 April 2012.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Roche disappointed with ISS recommendation
Friday April 6th 2012 01:00:00 PM

Roche released the following statement in response to a report issued by Institutional Shareholder Services (“ISS”) recommending that shareholders of Illumina, Inc. (NASDAQ: ILMN) vote against the election of Roche’s independent director nominees to Illumina’s Board of Directors

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Roche sends second letter to Illumina shareholders
Wednesday April 4th 2012 01:00:00 AM

Roche (SIX: RO, ROG; OTCQX: RHHBY) today sent a second letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to tender their shares into Roche’s increased offer and vote for Roche’s independent director nominees and other proposals at the 2012 Illumina annual meeting to be held on 18 April 2012.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
Tuesday April 3rd 2012 05:00:00 AM

By not engaging with Roche, Illumina reinforces notion of an entrenched Board. Roche released the following statement in response to the announcement by Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has recommended that shareholders not tender their shares to Roche’s increased offer.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati